Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough To Bring Tablet-Based Allergy Vaccine To U.S. Market

This article was originally published in The Pink Sheet Daily

Executive Summary

Company signs deal with Dutch firm ALK-Abello to develop and commercialize the vaccine, marketed as Grazax in Europe.

You may also be interested in...



Schering-Plough Gains Topical Antifungal In Deal With Anacor

Commercialization deal for the nail infection treatment is worth over $600 million for Palo Alto, Calif.-based Anacor.

Schering-Plough Gains Topical Antifungal In Deal With Anacor

Commercialization deal for the nail infection treatment is worth over $600 million for Palo Alto, Calif.-based Anacor.

Nasonex Indications Will Help Deflect Competition From Allermist, Schering-Plough Says

Company believes mometasone’s broader label, which includes indications for allergy symptoms in children two years and older, will differentiate the product from GlaxoSmithKline’s Flonase follow-on.

Topics

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel